Wall Street Zen Upgrades Cue Biopharma (NASDAQ:CUE) to “Buy”

Cue Biopharma (NASDAQ:CUE) was upgraded by equities research analysts at Wall Street Zen to a “buy” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cue Biopharma in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Cue Biopharma Trading Up 71.4%

Shares of Cue Biopharma stock opened at $0.50 on Friday. The firm’s 50 day simple moving average is $0.28 and its two-hundred day simple moving average is $0.46. The firm has a market capitalization of $48.82 million, a price-to-earnings ratio of -1.57 and a beta of 1.57. Cue Biopharma has a 12-month low of $0.17 and a 12-month high of $1.03.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Monday, March 16th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $21.94 million for the quarter. Cue Biopharma had a negative net margin of 96.85% and a negative return on equity of 165.19%. On average, sell-side analysts predict that Cue Biopharma will post -0.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CUE. Northwestern Mutual Wealth Management Co. raised its position in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma during the 3rd quarter valued at about $62,000. Stifel Financial Corp grew its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc increased its stake in shares of Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of Cue Biopharma in the 3rd quarter valued at about $439,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.